StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) stock

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3083% above fair value
$272.70−6.00 (-2.15%)

Close on Nov 18, 2026Market cap $656.47BP/E 41.4Yield 1.88%

Earnings

Johnson & Johnson's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Jan 20, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$25.40B
+5.8% on a year earlier
adjusted EPS*, Q3 FY2026
$2.59
$2.80 a year earlier
Latest guidance
Issued
Oct 13, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Johnson & Johnson's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 28, 2026Jan 20, 2027Expected–––––
Q3 FY2026ended Sep 27, 2026Oct 13, 2026before the open$25.40B+5.8%$0.09$2.59Release
Q2 FY2026ended Jun 28, 2026Jul 15, 2026before the open––––Release
Q1 FY2026ended Mar 29, 2026Apr 14, 2026before the open$24.06B+9.9%$2.14$2.70Release
Q4 FY2025ended Dec 28, 2025Jan 21, 2026before the open$24.60B+9.3%$2.10$2.46Release
Q3 FY2025ended Sep 28, 2025Oct 14, 2025before the open$24.00B+6.7%$2.12$2.80Release
Q2 FY2025ended Jun 29, 2025Jul 16, 2025before the open$23.74B+6.0%$2.29$2.77Release
Q1 FY2025ended Mar 30, 2025Apr 15, 2025before the open$21.89B+2.3%$4.54$2.77Release
Q4 FY2024ended Dec 29, 2024Jan 22, 2025before the open$22.50B+5.1%$1.41$2.04Release
Q3 FY2024ended Sep 29, 2024Oct 15, 2024before the open$22.50B+5.1%$1.11$2.42Release
Q2 FY2024ended Jun 30, 2024Jul 17, 2024before the open$22.40B-12.2%$1.93$2.82Release
Q1 FY2024ended Mar 31, 2024Apr 16, 2024before the open$21.40B-13.4%$2.20$2.71Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Johnson & Johnson's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Estimated Reported SalesGAAPFY2026$101.00B – $101.40B–NewOct 13, 2026
Estimated Reported Salesnon-GAAPFY2026$100.30B – $101.30B–NewApr 14, 2026
Estimated Reported SalesGAAPFY2026$100.00B – $101.00B–NewJan 21, 2026
Adjusted EPS (Diluted)non-GAAPFY2026$11.05 – $11.15–NewOct 13, 2026
Adjusted EPS (Diluted)non-GAAPFY2026$11.45 – $11.65$11.43 – $11.63RaisedApr 14, 2026
Adjusted EPS (Diluted) Change vs. Prior Yearnon-GAAPFY2026+7.5% – +8.9%–RaisedJul 15, 2026
Adjusted Operational EPS (Diluted) Change vs. Prior Yearnon-GAAPFY2026+6.6% – +8%–ReaffirmedJul 15, 2026
Estimated Reported Sales Change vs. Prior Yearnon-GAAPFY2026+7% – +7.6%–RaisedJul 15, 2026
Operational Sales Change vs. Prior Yearnon-GAAPFY2026+6.5% – +7.1%–NewJul 15, 2026

Guidance vs results

The last range Johnson & Johnson gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted Operational EPS (Diluted)$10.63 – $10.73$10.80Σ4QAbove range
FY2025Revenue$93.50B – $93.90B$94.24BΣ4QAbove range
FY2025Revenue growth+3.5% – +4%+6.12%Σ4QAbove range

Guidance history

Every forecast Johnson & Johnson put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 13, 2026Adjusted EPS (Diluted)FY2026$11.05 – $11.15New
Oct 13, 2026Estimated Reported SalesFY2026$101.00B – $101.40BNew
Jul 15, 2026Operational Sales Change vs. Prior YearFY2026+6.5% – +7.1%New
Jul 15, 2026Estimated Reported Sales Change vs. Prior YearFY2026+7% – +7.6%Raised
Jul 15, 2026Adjusted Operational EPS (Diluted) Change vs. Prior YearFY2026+6.6% – +8%Reaffirmed
Jul 15, 2026Adjusted EPS (Diluted) Change vs. Prior YearFY2026+7.5% – +8.9%Raised
Apr 14, 2026Adjusted EPS (Diluted)FY2026$11.45 – $11.65Raised
Apr 14, 2026Estimated Reported SalesFY2026$100.30B – $101.30BNew
Jan 21, 2026Adjusted EPS (Diluted)FY2026$11.43 – $11.63New
Jan 21, 2026Estimated Reported SalesFY2026$100.00B – $101.00BNew
Oct 14, 2025Adjusted Operational EPS (Diluted)FY2025$10.63 – $10.73Lowered
Oct 14, 2025Adjusted EPS (Diluted)FY2025$10.80 – $10.90Raised
Oct 14, 2025Estimated Reported SalesFY2025$93.50B – $93.90BRaised
Oct 14, 2025Adjusted Operational SalesFY2025+3.5% – +4%New
Oct 14, 2025Operational SalesFY2025$93.00B – $93.40BLowered
Jul 16, 2025Adjusted EPS (Diluted)FY2025$10.80 – $10.90New
Jul 16, 2025Estimated Reported SalesFY2025$93.20B – $93.60BNew
Apr 15, 2025Adjusted Operational Sales Change vs. Prior YearFY2025+2% – +3%New
Jan 22, 2025Adjusted Operational EPS (Diluted)FY2025$10.75 – $10.95New
Jan 22, 2025Adjusted EPS (Diluted)FY2025$10.50 – $10.70Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Adjusted figures

Non-GAAP numbers Johnson & Johnson reports itself, taken from its earnings releases

MeasureQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025FY2025
Adjusted Net Earnings$6.34B$7.08B$6.61B$6.01B$26.22B
adjusted EPS*$2.59$2.90$2.70$2.46$10.79
Free Cash Flow–$8.70B$1.50B–$19.70B

Read from the company's own earnings releases; hover a figure for the sentence it came from. Companies choose what to leave out of an adjusted number and there is no standard for it, so these are not comparable between companies the way the audited statements are. Margins here are computed from the adjusted revenue of the same period.

Press releases

Releases Johnson & Johnson filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. Update
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?